Sign in

    Tom Stephan

    Research Analyst at Stifel

    Tom Stephan is an Associate Vice President and Equity Analyst at Stifel, specializing in Healthcare with a focus on Medical Technology & Supplies. He actively covers companies such as Alcon (ALC), STAAR Surgical, Glaukos, RxSight, and Sight Sciences, issuing research reports including price targets and ratings that reflect his analysis of industry conditions. Since joining Stifel in 2016, based in New York, he has consistently provided in-depth recommendations, such as maintaining a 'Buy' rating on Alcon while adjusting target prices in response to market shifts; performance data like average 12-month ROI is not publicly disclosed. Stephan holds a Bachelor of Business Administration in Finance from the University of Notre Dame’s Mendoza College of Business, with professional experience rooted at Stifel since graduation.

    Tom Stephan's questions to ALCON (ALC) leadership

    Tom Stephan's questions to ALCON (ALC) leadership • Q1 2025

    Question

    Tom Stephan of Stifel inquired about the outlook for Alcon's legacy contact lens portfolio and asked for more detail on the company's confidence in its U.S. IOL market share despite strong competitive momentum.

    Answer

    CEO David Endicott stated that while legacy contact lenses are a drag, the mix shift to newer, higher-margin products is beneficial for profitability. On U.S. IOL share, he acknowledged some share loss from historical peaks but emphasized the durability of the PanOptix and Vivity brands. He noted that strong international share gains have resulted in a relatively flat overall global share position.

    Ask Fintool Equity Research AI